Combined peptides shown to help wounds
Researchers then applied the wound-healing peptide with a peptide created during a prior study. Combined, they out-performed control groups, including becaplermin. Becaplermin is the only federally approved growth factor-containing drug for treating diabetic wounds, according to Tatiana Demidova-Rice, Ph.D.
“The confirmation that these peptides could act synergistically to improve human wound healing moves our research one significant step closer to clinical application,” added Ira Herman, Ph.D.
“The wound-healing peptides should also prove strategic as we continue developing ‘smart' devices or fully-vascularized living tissue constructs for patients suffering with diabetic plantar or venous stasis ulcers,” Herman said.
Full findings appear in the journal PLoS ONE.